Promising c. diff drug trial halted after just 3 patients
NCT ID NCT06536465
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug called REC-3964 to see if it could prevent repeat Clostridioides difficile (C. diff) infections in adults. Only 3 people were enrolled before the trial was stopped early. The goal was to check safety and whether the drug helped people stay infection-free for 8 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- REC-3964
- What this could lead to
- If it works, this could point toward a new treatment to prevent repeat C. diff infections.
- What could go wrong
- The trial was terminated early with only 3 participants, so we have very little data. It is unclear if REC-3964 is safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GANJ - Toms River - Ocean Family Gastroenterology
Toms River, New Jersey, 08755, United States
-
Southern Star Research Institute, LLC
San Antonio, Texas, 78229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.